Chinese Medical Sciences Journal ›› 2021, Vol. 36 ›› Issue (1): 1-16.doi: 10.24920/003864
• • 下一篇
收稿日期:
2020-12-10
接受日期:
2020-12-14
出版日期:
2021-01-14
发布日期:
2021-01-14
Qiwen Yang1,Xiaoling Ma2,Fupin Hu3,Jing Zhang3,Tongwen Sun4,Baiyi Chen5,Yingchun Xu1,*(),Youning Liu6,*(),China Medical Education Association ,Expert Committee on Infectious Diseases, China Medical Education Association
Received:
2020-12-10
Accepted:
2020-12-14
Published:
2021-01-14
Online:
2021-01-14
Contact:
Yingchun Xu,Youning Liu
E-mail:xycpumch@139.com;liuyn301@126.com
Qiwen Yang,Xiaoling Ma,Fupin Hu,Jing Zhang,Tongwen Sun,Baiyi Chen,Yingchun Xu,Youning Liu,China Medical Education Association ,Expert Committee on Infectious Diseases, China Medical Education Association . Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation[J].Chinese Medical Sciences Journal, 2021, 36(1): 1-16.
"
Testing method and organisms | Drug tested | Strains in terms of the indicated BMD-MIC values, n (%) | Performance evaluation (%) | |||||
---|---|---|---|---|---|---|---|---|
MIC ≤2 mg/L | MIC ≥4 mg/L | EA | CA | VME | ME | |||
E-test | ||||||||
Enterobacterales | Polymyxin B [ | 220 (95.7) | 10 (4.4) | 95.6 | 99.1 | 20.0 | 0 | |
Enterobacterales | Polymyxin B [ | 53 (69.7) | 23 (30.3) | 48.7 | 89.5 | 26.1 | 1.9 | |
Enterobacterales | Colistin [ | 51 (67.1) | 25 (32.9) | 75 | 92.1 | 12 | 5.9 | |
Enterobacterales | Colistin [ | 219 (67.4) | 106 (32.6) | 80.6 | 96.3 | 9.4 | 0.9 | |
E. coli | Colistin [ | 48 (90.6) | 5 (9.4) | 92.5 | 96.2 | 40.0 | 0 | |
K. pneumoniae | Colistin [ | 126 (61.2) | 80 (38.8) | 79.8 | 99 | 1.6 | 2.5 | |
E. cloacae | Colistin [ | 23 (59.0) | 16 (41.0) | 72.2 | 87.2 | 25.0 | 4.3 | |
P. aeruginosa | Colistin [ | 78 (100) | 0 (0) | 79.5 | 93.6 | - | 6.4 | |
A. baumannii | Colistin [ | 2 (10.0) | 18 (90.0) | 55.0 | 65.0 | 38.9 | 0 | |
A. baumannii | Colistin [ | 42 (100) | 0 (0) | 11.9 | 100 | - | 0 | |
A. baumannii | Polymyxin B [ | 42 (100) | 0 (0) | 85.7 | 100 | - | 0 | |
Disk diffusion method | ||||||||
Enterobacterales | IE | IE | IE | NA | IE | IE | IE | |
P. aeruginosa | Colistin [ | 78 (100) | 0 (0) | NA | 100 | - | 0 | |
A. baumannii | IE | IE | IE | NA | IE | IE | IE | |
BD Phoenix | ||||||||
Enterobacterales | Colistin [ | 219 (67.4) | 106 (32.6) | 76.1 | 92.0 | 24.5 | 0 | |
E. coli | Colistin [ | 48 (90.6) | 5 (9.4) | - | 98.1 | 20.0 | 0 | |
K. pneumoniae | Colistin [ | 126 (61.2) | 80 (38.8) | - | 96.1 | 10.0 | 0 | |
E. cloacae | Colistin [ | 23 (59.0) | 16 (41.0) | - | 64.1 | 87.5 | 0 | |
P. aeruginosa | IE | IE | IE | IE | IE | IE | IE | |
A. baumannii | Colistin [ | 88 (75.2) | 29 (24.8) | 91.5 | 88.9 | 41.4 | 1.1 | |
MicroScan | ||||||||
Gram-negative bacteria | Colistin [ | 52 (28.1) | 133 (71.9) | IE | 91.9 | 0.8 | 26.9 | |
Enterobacterales | Colistin [ | 44 (57.9) | 32 (42.1) | IE | 88.2 | 4.0 | 15.8 | |
Enterobacterales | Colistin [ | 32 (21.9) | 114 (78.1) | IE | 99.3 | 0 | 3.1 | |
Non-fermentative organism | Colistin [ | 20 (51.3) | 19 (48.7) | IE | 64.1 | 5.3 | 65.0 | |
Vitek 2 | ||||||||
Enterobacterales | Colistin [ | 60 (75.9) | 16 (24.1) | 93.4 | 88.2 | 36.0 | 0 | |
Enterobacterales | Polymyxin B [ | 47 (61.8) | 29 (38.2) | 96.1 | 94.7 | 3.7 | 6.1 | |
Enterobacterales | Colistin [ | 219 (67.4) | 106 (32.6) | 75.9 | 90.5 | 29.2 | 0 | |
E. coli | Colistin [ | 48 (90.6) | 5 (9.4) | - | 94.3 | 60.0 | 0 | |
K. pneumoniae | Colistin [ | 126 (61.2) | 80 (38.8) | 81.7 | 94.2 | 15.0 | 0 | |
K. pneumoniae | Colistin [ | 1 (2.4) | 40 (97.6) | 75.6 | 100 | 0 | 0 | |
E. cloacae | Colistin [ | 23 (59.0) | 16 (41.0) | - | 66.7 | 81.3 | 0 | |
P. aeruginosa | IE | IE | IE | IE | IE | IE | IE | |
A. baumannii | Colistin [ | 88 (75.2) | 29 (24.8) | 88.9 | 89.7 | 37.9 | 1.1 | |
A. baumannii | Colistin [ | 42 (100) | 0 (0) | 26.2 | 100 | - | 0 | |
A. baumannii | Polymyxin B [ | 42 (100) | 0 (0) | 57.1 | 100 | - | 0 | |
Agar dilution method | ||||||||
A. baumannii | Colistin [ | 88 (75.2) | 29 (24.8) | 93.2 | 87.2 | 3.4 | 15.9 | |
A. baumannii | Colistin [ | 42 (100) | 0 (0) | 92.8 | 85.7 | - | 16.7 | |
A. baumannii | Polymyxin B [ | 42 (100) | 0 (0) | 76.2 | 100 | - | 0 | |
Colistin agar test | ||||||||
Enterobacterales | Colistin [ | 152 (43.7) | 196 (56.3) | 99.7 | 99.7 | 0.5 | 0 | |
P. aeruginosa | Colistin [ | 135 (91.2) | 13 (8.8) | 99.3 | 100 | 0 | 0 | |
A. baumannii | Colistin [ | 60 (45.8) | 71 (54.2) | 88.5 | 92.3 | 14.3 | 0 | |
Colistin broth disk elution | ||||||||
Enterobacterales | Colistin [ | 152 (43.7) | 196 (56.3) | 94.3 | 98.6 | 2.5 | 0 | |
P. aeruginosa | Colistin [ | 135 (91.2) | 13 (8.8) | 96.6 | 99.3 | 0 | 0.7 | |
A. baumannii | Colistin [ | 60 (45.8) | 71 (54.2) | 93.1 | 95.4 | 5.6 | 3.3 |
"
Species | CLSI 2019 (mg/L) | CLSI 2019 (mg/L) | CLSI 2020 (mg/L) | EUCAST 2020 (mg/L) | USCAST 2020 (mg/L)a | USFDA 2020 (mg/L) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Colistin | Polymyxin B | Colistin or polymyxin B | Colistin | Colistin or polymyxin B | Colistin or polymyxin B | |||||||||||||||
S | I | R | S | I | R | I | R | S | R | ATU | S | R | I | R | ||||||
Enterobac- terales | - | - | - | - | - | - | ≤2 | ≥4 | ≤2 | >2 | - | ≤2 | ≥4 | - | - | |||||
P. aeruginosa | ≤2 | - | ≥4 | ≤2 | 4 | ≥8 | ≤2 | ≥4 | ≤2 | >2 | 4 | ≤2 | ≥4 | Reb | Reb | |||||
A. baumannii | ≤2 | - | ≥4 | ≤2 | - | ≥4 | ≤2 | ≥4 | ≤2 | >2 | - | ≤2 | ≥4 | Nc | Nc |
"
Drug | Animal model | Species | PK/PD target values required to achieve CFU reduction (medians) | |
---|---|---|---|---|
1-log10 | 2-log10 | |||
Colistin[ | Murine thigh infection | P. aeruginosa | 6.6 - 10.9 | 7.4 - 13.7 |
Colistin[ | Murine thigh infection | A. baumannii | 3.5 - 13.9 | 7.4 - 17.6 |
Colistin[ | Murine pneumonia | P. aeruginosa | 43.3 - 57.9 | 51.8 - 105 |
Colistin[ | Murine pneumonia | A. baumannii | 20.8 | 36.8 |
Polymyxin B[ | Murine hind limbs infection | K. pneumoniae | 3.7 - 28.0 | / |
"
Dosing regimen | Sources | K. pneumoniae | E. coli | ||||
---|---|---|---|---|---|---|---|
PTA (%) | CFR | PTA (%) | CFR | ||||
MIC50=0.5 | MIC90=2 | MIC50=0.5 & MIC90=0.5 | |||||
CrCl ≥80 mL/min | |||||||
150 mg, q12h | EMA,[ | 92.7 | 64.4 | 85.4 | 92.7 | 90.4 | |
180 mg, q12h | Nation [ | 97.9 | 69.2 | 87.9 | 97.9 | 92.3 | |
150 mg, q8h | Siriraj Hospital regimen [ | 98.7 | 79.7 | 92.0 | 98.7 | 95.1 | |
CrCl 51 to 79 mL/min | |||||||
114 mg, q12h | FDA [ | 96.0 | 72.0 | 89.9 | 96.0 | 94.1 | |
150 mg, q12h | Siriraj Hospital regimen,[ | 97.3 | 78.3 | 92.7 | 97.3 | 95.8 | |
CrCl 30 to 50 mL/min | |||||||
150 mg, q12h | FDA [ | 97.6 | 71.1 | 91.3 | 97.6 | 95.6 | |
100 mg, q12h | Siriraj Hospital regimen [ | 98.9 | 85.7 | 95.7 | 98.9 | 97.9 | |
110 mg, q12h | Nation [ | 99.0 | 87.4 | 96.4 | 99.0 | 98.2 | |
125 mg, q12h | EMA [ | 99.2 | 89.8 | 97.2 | 99.2 | 98.5 | |
CrCl 11 to 29 mL/min | |||||||
60 mg, q24h | FDA [ | 96.3 | 56.2 | 86.3 | 96.3 | 97.9 | |
150 mg, q24h | EMA,[ | 99.7 | 89.4 | 97.4 | 99.7 | 99.6 | |
180 mg, q24h | Nation [ | 99.6 | 89.3 | 97.4 | 99.6 | 99.9 | |
CrCl ≤10 mL/min | |||||||
60 mg, q24h | FDA [ | 99.5 | 77.1 | 94.5 | 99.5 | 100 | |
120 mg, q24h | EMA [ | 99.9 | 94.9 | 98.9 | 99.9 | 100 | |
150 mg, q24h | Nation [ | 100 | 97.4 | 99.5 | 100 | 100 |
"
CrCl (mL/min) | MIC (mg/L) | PTA of different polymyxin B dosing regimens (%) | ||||
---|---|---|---|---|---|---|
1.5 mg/(kg·d) | 2.0 mg/(kg·d) | 2.5 mg/(kg·d) | 3.0 mg/(kg·d) | Loading dose 2.5 mg/kg + 2.5 mg/(kg·d) | ||
34 | 0.03125 | 100 | 100 | 100 | 100 | 100 |
0.0625 | 100 | 100 | 100 | 100 | 100 | |
0.125 | 100 | 100 | 100 | 100 | 100 | |
0.25 | 99.3 | 99.8 | 99.9 | 99.9 | 100 | |
0.5 | 19.0 | 64.0 | 97.0 | 99.3 | 99.8 | |
1 | 0.1 | 1.8 | 3.0 | 7.6 | 19.5 | |
2 | 0 | 0 | 0 | 0.1 | 1.7 | |
105 | 0.03125 | 100 | 100 | 100 | 100 | 100 |
0.0625 | 100 | 100 | 100 | 100 | 100 | |
0.125 | 96.0 | 99.0 | 100 | 100 | 100 | |
0.25 | 69.0 | 84.0 | 92.0 | 96.0 | 99.0 | |
0.5 | 15.0 | 38.0 | 57.9 | 70.0 | 81.0 | |
1 | 0.1 | 0.2 | 7.0 | 15.0 | 35.0 | |
2 | 0 | 0 | 0 | 0.1 | 1.7 | |
178 | 0.03125 | 100 | 100 | 100 | 100 | 100 |
0.0625 | 100 | 100 | 100 | 100 | 100 | |
0.125 | 74.0 | 97.0 | 99.0 | 100 | 100 | |
0.25 | 15.0 | 32.0 | 56.0 | 78.0 | 94.0 | |
0.5 | 1.0 | 4.0 | 8.0 | 15.0 | 27.0 | |
1 | 0 | 0 | 0.6 | 1 | 0 | |
2 | 0 | 0 | 0 | 0 | 0 |
"
Dosing regimen | Body weight (kg) | PTA at indicated MIC level (%) | ||||||
---|---|---|---|---|---|---|---|---|
0.125 mg/L | 0.25 mg/L | 0.5 mg/L | 1 mg/L | 2 mg/L | 4 mg/L | 8 mg/L | ||
100 mg q12h | ||||||||
50 | 100 | 100 | 100 | 39.1 | 2.0 | 0.2 | 0 | |
75 | 100 | 100 | 99.9 | 24.7 | 1.1 | 0.1 | 0 | |
110 | 100 | 100 | 94.3 | 16.5 | 0.8 | 0 | 0 | |
1 mg/kg TBW q12h | ||||||||
50 | 100 | 100 | 39.1 | 2 | 0.2 | 0 | 0 | |
75 | 100 | 100 | 82.1 | 7.7 | 0.3 | 0 | 0 | |
110 | 100 | 100 | 97.6 | 24.4 | 0.2 | 0.1 | 0 | |
1.5 mg/kg TBW q12h | ||||||||
50 | 100 | 100 | 93.5 | 10.7 | 0.3 | 0 | 0 | |
75 | 100 | 100 | 99.7 | 40.2 | 2.1 | 0.1 | 0 | |
110 | 100 | 100 | 100 | 74.7 | 7.6 | 0.3 | 0 | |
Loading dose 2.5 mg/kg + 100 mg q12h | ||||||||
50 | 100 | 100 | 100 | 61.3 | 3.1 | 0.2 | 0 | |
75 | 100 | 100 | 100 | 81.3 | 8.2 | 0.3 | 0 | |
110 | 100 | 100 | 100 | 93.1 | 16.8 | 0.9 | 0 | |
Loading dose 2.5 mg/kg + 1.5 mg/kg TBW q12h | ||||||||
50 | 100 | 100 | 100 | 45.0 | 2.0 | 0.2 | 0 | |
75 | 100 | 100 | 100 | 85.5 | 9.0 | 0.3 | 0 | |
110 | 100 | 100 | 100 | 98.2 | 26.8 | 1.5 | 0.1 |
"
Baiyi Chen | Department of Infectious Diseases, the First Affiliated Hospital of China Medical University |
---|---|
Yihai Gu | Department of Laboratory Medicine, Hanzhong 3201 Hospital |
Li Gu | Department of Infectious Diseases, Beijing Chaoyang Hospital affiliated to Capital Medical University |
Fupin Hu | Institute of Antibiotics, Huashan Hospital, Fudan University |
Jihong Hu | National Center for Clinical Laboratories |
Yunjian Hu | Department of Laboratory Medicine, Beijing Hospital |
Zhidong Hu | Department of Laboratory Medicine, Tianjin Medical University General Hospital |
Mei Kang | Department of Laboratory Medicine, West China Hospital, Sichuan University |
Jian Li | Monash University, Australia |
Junming Li | Department of Laboratory Medicine, the First Affiliated Hospital of Nanchang University |
Xin Li | Department of Pharmacy, the Third Hospital of Changsha |
Yi Li | Department of Laboratory Medicine, Henan Provincial People’s Hospital |
Kang Liao | Department of Laboratory Medicine, the First Affiliated Hospital, Sun Yat-Sen University |
Yongping Lin | Department of Laboratory Medicine, the First Affiliated Hospital of Guangzhou Medical University |
Wen’en Liu | Department of Laboratory Medicine, Xiangya Hospital, Central South University |
Yong Liu | Department of Laboratory Medicine, Shengjing Hospital affiliated to China Medical University |
Youning Liu | Department of Respiratory Medicine, the First Medical Center of PLA General Hospital |
Yuqing Liu | Shandong Academy of Agricultural Sciences |
Zhengyin Liu | Department of Infectious Diseases, Peking Union Medical College Hospital |
Zhiming Lu | Department of Laboratory Medicine, Shandong Provincial Hospital |
Xiaoju Lv | Department of Infectious Diseases, West China Hospital, Sichuan University |
Yuan Lv | Institute of Clinical Pharmacology, Peking University First Hospital |
Xiaojun Ma | Department of Infectious Diseases, Peking Union Medical College Hospital |
Xiaoling Ma | Department of Laboratory Medicine, the First Affiliated Hospital, University of Science and Technology of China |
Dan Mei | Department of Pharmacy, Peking Union Medical College Hospital |
Yuxing Ni | Department of Clinical Microbiology, Ruijin Hospital affiliated to Shanghai Jiao Tong University |
Ziyong Sun | Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
Tongwen Sun | General ICU, the First Affiliated Hospital of Zhengzhou University |
Yiwei Tang | Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, USA |
Minggui Wang | Institute of Antibiotics, Huashan Hospital, Fudan University |
Rui Wang | Laboratory of Clinical Pharmacology, the First Medical Center of PLA General Hospital |
Lianhua Wei | Department of Laboratory Medicine, Gansu Provincial People’s Hospital |
Wenjuan Wu | Department of Laboratory Medicine, Shanghai East Hospital affiliated to Tongji University |
Yingchun Xu | Department of Laboratory Medicine, Peking Union Medical College Hospital |
Boren Xue | Department of Infectious Diseases, Affiliated Hospital of Taiwan University School of Medicine |
Bin Yang | Department of Laboratory Medicine, the First Affiliated Hospital of Fujian Medical University |
Qiwen Yang | Department of Laboratory Medicine, Peking Union Medical College Hospital |
Qing Yang | Department of Laboratory Medicine, the First Affiliated Hospital of Zhejiang University School of Medicine |
Yunsong Yu | Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
Hua Yu | Department of Laboratory Medicine, Sichuan Provincial People’s Hospital |
Jing Zhang | Institute of Antibiotics, Huashan Hospital, Fudan University |
Xiuzhen Zhang | Department of Laboratory Medicine, Beijing Hospital |
Jianhong Zhao | Department of Laboratory Medicine, the Second Hospital of Hebei Medical University |
Bo Zheng | Department of Infection, Peking University People’s Hospital |
Demei Zhu | Institute of Antibiotics, Huashan Hospital, Fudan University |
Lei Zhu | Department of Laboratory Medicine, Shanxi Children’s Hospital |
Chao Zhuo | Guangzhou Institute of Respiratory Health |
1. | Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th Edition. USA: Wayne, 2020. P. 38-48. |
2. | The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020.http://www.eucast.org . |
3. |
Pogue JM, Jones RN, Bradley JS, et al. Polymyxin susceptibility testing and interpretive breakpoints: recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrob Agents Chemother 2020; 64:e01495-19. doi: 10.1128/AAC.01495-19.
doi: 10.1128/AAC.01495-19 pmid: 31767718 |
4. | Li HQ, Niu M, Liu SM, et al. Susceptibility of CRE to polymyxin B and the difference between two testing methods. Chin J Infect Control 2019; 18(11):1059-63.Chinese. |
5. |
Chew KL, La MV, Lin RTP, et al. Colistin and Polymyxin B susceptibility testing for carbapenem-resistant and MCR-positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution. J Clin Microbiol 2017; 55(9):2609-16. doi: 10.1128/JCM.00268-17.
doi: 10.1128/JCM.00268-17 pmid: 28592552 |
6. |
Pfennigwerth N, Kaminski A, Korte-Berwanger M, et al. Evaluation of six commercial products for colistin susceptibility testing in Enterobacterales. Clin Microbiol Infect 2019; 25(11):1385-9. doi: 10.1016/j.cmi.2019.03.017.
doi: 10.1016/j.cmi.2019.03.017 pmid: 30928563 |
7. |
Dafopoulou K, Zarkotou O, Dimitroulia E, et al. Comparative evaluation of colistin susceptibility testing methods among carbapenem-nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 2015; 59(8):4625-30. doi: 10.1128/AAC.00868-15.
doi: 10.1128/AAC.00868-15 pmid: 26014928 |
8. |
van der Heijden IM, Levin AS, de Pedri EH, et al. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann Clin Microbiol Antimicrob 2007; 6:8. doi: 10.1186/1476-0711-6-8.
doi: 10.1186/1476-0711-6-8 pmid: 17697363 |
9. |
Singhal L, Sharma M, Verma S, et al. Comparative evaluation of broth microdilution with polystyrene and glass-coated plates, agar dilution, E-Test, Vitek, and disk diffusion for susceptibility testing of colistin and polymyxin B on carbapenem-resistant clinical isolates of Acinetobacter baumannii. Microb Drug Resist 2018; 24(8):1082-8. doi: 10.1089/mdr.2017.0251.
doi: 10.1089/mdr.2017.0251 pmid: 29406804 |
10. |
Vourli S, Dafopoulou K, Vrioni G, et al. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2017; 72(9):2528-30. doi: 10.1093/jac/dkx186.
doi: 10.1093/jac/dkx186 pmid: 28605445 |
11. |
Jayol A, Nordmann P, Andre C, et al. Evaluation of three broth microdilution systems to determine colistin susceptibility of Gram-negative bacilli. J Antimicrob Chemother 2018; 73(5):1272-8. doi: 10.1093/jac/dky012.
doi: 10.1093/jac/dky012 pmid: 29481600 |
12. |
Humphries RM, Green DA, Schuetz AN, et al. Multicenter evaluation of colistin broth disk elution and colistin agar test: a report from the clinical and laboratory standards institute. J Clin Microbiol 2019; 57(11):e01269-19. doi: 10.1128/JCM.01269-19.
doi: 10.1128/JCM.01269-19 pmid: 31511331 |
13. | CLSI. Performance standards for antimicrobial susceptibility testing. 29th ed. CLSI supplement M100. Pennsylvania: Clinical and Laboratory Standards Institute, 2019. |
14. | U.S. Food & Drug Administration. Antibacterial Susceptibility Test Interpretive Criteria. Available from https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria . Accessed: November 9, 2020. |
15. | European Committee on Antimicrobial Susceptibility Testing. The EUCAST Subcommittee on MIC distributions and ECOFFs. Available from https://mic.eucast.org/Eucast2/SearchController/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=837&Specium=-1 . Accessed: November 9, 2020. |
16. |
Cheah SE, Wang J, Nguyen VT, et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 2015; 70(12):3291-7. doi: 10.1093/jac/dkv267.
doi: 10.1093/jac/dkv267 pmid: 26318190 |
17. |
Landersdorfer CB, Wang J, Wirth V, et al. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother 2017; 73(2):462-8. doi: 10.1093/jac/dkx409.
doi: 10.1093/jac/dkx409 pmid: 29149294 |
18. |
Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39(1):10-39. doi: 10.1002/phar.2209.
doi: 10.1002/phar.2209 pmid: 30710469 |
19. | European Medicines Agency. European Medicines Agency completes review of polymyxin-based medicines. https://www.ema.europa.eu/en/news/european-medicines-agency-completes-review-polymyxin-based-medicines. Released October 24, 2014; accessed November 9, 2020. |
20. | FDA Approved Drug Products. Label and Approval History for Coly-Mycin M, NDA 050108. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050108s033lbl.pdf. Accessed November 9, 2020. |
21. |
Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis 2017; 64(5):565-71. doi: 10.1093/cid/ciw839.
doi: 10.1093/cid/ciw839 pmid: 28011614 |
22. |
Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65(12):2645-9. doi: 10.1093/jac/dkq360.
doi: 10.1093/jac/dkq360 pmid: 20876621 |
23. | Jitaree K, Sathirakul K, Houngsaitong J, et al. Pharmacokinetic/Pharmacodynamic (PK/PD) simulation for dosage optimization of colistin against carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Escherichia coli. Antibiotics (Basel) 2019; 8(3):125. doi: 10.3390/antibiotics8030125. |
24. |
Avedissian S, Miglis C, Kubin CJ, et al. Polymyxin B pharmacokinetics in adult cystic fibrosis patients. Pharmacotherapy 2018; 38(7):730-8. doi: 10.1002/phar.2129.
doi: 10.1002/phar.2129 pmid: 29800496 |
25. |
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63(5):575-82. doi: 10.1093/cid/ciw504. Erratum in Clin Infect Dis 2017; 64(9):1298. Doi 10.1093/cid/ciw799; Clin Infect Dis 2017; 65(8):1435; doi 10.1093/cid/cix587; Clin Infect Dis 2017; 65(12):2161. doi 10.1093/cid/cix759.
doi: 10.1093/cid/ciw504 pmid: 27521441 |
26. |
Miglis C, Rhodes NJ, Avedissian S, et al. Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother 2018; 62(3):e01475-17. doi: 10.1128/AAC.01475-17.
doi: 10.1128/AAC.01475-17 pmid: 29311071 |
27. | Society of Critical Care Medicine, Society of Evi-dence-based and Translational Infectious Diseases of Chinese Research Hospital Association. Chinese expert consensus on clinical use of polymyxins. Chin Critic Care Med 2019; 28(10):1218-22. Chinese. doi: 10.3760/cma.j.issn.2095-4352.2019.10.003. |
28. |
Medeiros GS, Rigatto MH, Falci DR, et al. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents 2019; 53(2):152-7. doi: 10.1016/j.ijantimicag.2018.10.010.
doi: 10.1016/j.ijantimicag.2018.10.010 pmid: 30722960 |
29. |
Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55(7):943-50. doi: 10.1093/cid/cis588.
doi: 10.1093/cid/cis588 pmid: 22752516 |
30. |
Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33(8):1311-22. doi: 10.1007/s10096-014-2070-6.
doi: 10.1007/s10096-014-2070-6 pmid: 24532009 |
31. |
Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014; 58(9):5598-601. doi: 10.1128/AAC.02435-13.
doi: 10.1128/AAC.02435-13 pmid: 24982065 |
32. |
Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9.
doi: 10.1016/S1473-3099(18)30099-9 pmid: 29456043 |
33. |
Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care 2016; 6(1):26. doi: 10.1186/s13613-016-0127-7.
doi: 10.1186/s13613-016-0127-7 pmid: 27033711 |
34. |
Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia. Crit Care Med 2015; 43(3):527-33. doi: 10.1097/CCM.0000000000000771.
doi: 10.1097/CCM.0000000000000771 pmid: 25493971 |
35. |
Vardakas KZ, Voulgaris GL, Samonis G, et al. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Int J Antimicrob Agents 2018; 51(1):1-9. doi: 10.1016/j.ijantimicag.2017.05.016.
doi: 10.1016/j.ijantimicag.2017.05.016 pmid: 28669836 |
36. |
de Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol 2016; 23(1):68-75. doi: 10.1111/ene.12789.
pmid: 26228051 |
37. |
Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007; 29(1):9-25. doi: 10.1016/j.ijantimicag.2006.08.024.
doi: 10.1016/j.ijantimicag.2006.08.024 pmid: 17126534 |
38. |
Couet W, Gregoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011; 89(6):875-9. doi: 10.1038/clpt.2011.48.
doi: 10.1038/clpt.2011.48 pmid: 21544080 |
39. |
Sorlí L, Luque S, Li J, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical. J Infect 2019; 79(3):253-61. doi: 10.1016/j.jinf.2019.06.011.
pmid: 31265867 |
40. |
Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis 2019; 23(1):60-5. doi: 10.1016/j.bjid.2018.12.004.
doi: 10.1016/j.bjid.2018.12.004 pmid: 30796888 |
41. |
Rigatto MH, Falci DR, Lopes NT, et al. Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. Int J Antimicrob Agents 2016; 47(2):146-50. doi: 10.1016/j.ijantimicag.2015.11.007.
doi: 10.1016/j.ijantimicag.2015.11.007 pmid: 26742727 |
42. |
Ismail B, Shafei MN, Harun A, et al. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. J Microbiol Immunol Infect 2018; 51(6):763-9. doi: 10.1016/j.jmii.2017.03.007.
doi: 10.1016/j.jmii.2017.03.007 pmid: 28716359 |
43. |
Dickstein Y, Lellouche J, Ben DAM, et al. Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial. Clin Infect Dis 2019; 69(5):769-76. doi: 10.1093/cid/ciy988.
doi: 10.1093/cid/ciy988 pmid: 30462182 |
44. |
Mattos KPH, Gouvêa IR, Quintanilha JCF, et al. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment. J Clin Pharm Ther 2019; 44(3):415-9. doi: 10.1111/jcpt.12801.
doi: 10.1111/jcpt.12801 pmid: 30666679 |
45. |
Maniara BP, Healy LE, Doan T. Risk of nephrotoxicity associated with nonrenally adjusted intravenous polymyxin b compared to traditional dosing. J Pharm Pract 2020; 33(3):287-92. doi: 10.1177/0897190018799261.
doi: 10.1177/0897190018799261 pmid: 30253682 |
46. |
Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, et al. Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 2015; 59(6):3224-32. doi: 10.1128/AAC.00280-15.
doi: 10.1128/AAC.00280-15 pmid: 25801556 |
47. |
Liu Q, Li W, Feng Y, et al. Efficacy and safety of polymyxins for the treatment of Acinetobacter baumannii infection: a systematic review and meta-analysis. PLoS One 2014; 9(6):e98091. doi: 10.1371/journal.pone.0098091.
doi: 10.1371/journal.pone.0098091 pmid: 24911658 |
48. |
Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007; 58(2):235-40. doi: 10.1016/j.diagmicrobio.2007.01.008.
doi: 10.1016/j.diagmicrobio.2007.01.008 pmid: 17350201 |
No related articles found! |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
|
Supervised by National Health Commission of the People's Republic of China
9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China
Tel: 86-10-65105897 Fax:86-10-65133074
E-mail: cmsj@cams.cn www.cmsj.cams.cn
Copyright © 2018 Chinese Academy of Medical Sciences
All right reserved.
京公安备110402430088 京ICP备06002729号-1